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Objective:  Although  vaccine  coverage  in infants  in  sub-Saharan  Africa  is high,  this  is  estimated  at  the
age  of 6–12  months.  There  is little  information  on  the timely  administration  of  birth  dose  vaccines.  The
objective  of  this  study  was to assess  the  timing  of  birth  dose  vaccines  (hepatitis  B, BCG  and  oral  polio)
and  reasons  for delayed  administration  in  The  Gambia.
Methods:  We used  vaccination  data  from  the Farafenni  Health  and  Demographic  Surveillance  System
(FHDSS)  between  2004  and  2014.  Coverage  was calculated  at birth  (0–1  day),  day  7, day  28,  6  months
and  1 year of  age.  Logistic  regression  models  were  used  to identify  demographic  and  socio-economic
variables  associated  with  vaccination  by  day 7 in children  born  between  2011  and  2014.
Results:  Most  of  the  10,851  children  had  received  the  ﬁrst  dose  of hepatitis  B virus  (HBV)  vaccine  by  the
age  of 6 months  (93.1%).  Nevertheless,  only  1.1%  of  them  were  vaccinated  at  birth,  5.4%  by day  7,  and
58.4%  by  day  28. Vaccination  by day 7 was  associated  with  living  in  urban  areas  (West  rural:  adjustedest Africa OR  (AOR)  =  6.13,  95%CI:  3.20–11.75,  east  rural: AOR  = 6.72,  95%CI:  3.66–12.33)  and  maternal  education
(senior-educations:  AOR  =  2.43,  95%CI:  1.17–5.06);  and inversely  associated  with  distance  to vaccination
delivery  points  (2 km:  AOR  = 0.41,  95%CI:  0.24–0.70),  and Fula  ethnicity  (AOR  =  0.60,  95%CI:  0.40–0.91).
Conclusion:  Vaccine  coverage  in  The  Gambia  is  high  but infants  are  usually  vaccinated  after  the  neonatal
period.  Interventions  to ensure  the implementation  of  national  vaccination  policies  are  urgently  needed.
ublis© 2016  The  Authors.  P
. Introduction
The Expanded Programme on Immunization (EPI) is an essential,
ost-effective health intervention able to reduce child morbid-
ty and mortality worldwide [1]. The World Health Organization
WHO) recommends to administer three vaccines soon after birth,
amely hepatitis B virus (HBV) vaccine, Bacillus Calmette-Guerin
BCG) and oral polio vaccine (OPV) [2–4]. Their early administration
ims at preventing both mother-to-child and early horizontal HBV
ransmission [4]; TB meningitis in childhood [5]; and to increase
∗ Corresponding author at: Atlantic Road, Fajara, PO Box 273, Banjul, The Gambia.
el.: +220 449544x2305.
E-mail address: aroca@mrc.gm (A. Roca).
ttp://dx.doi.org/10.1016/j.vaccine.2016.05.017
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
OPV sero-conversion rates with subsequent doses [3]. Among the
49 countries in sub-Saharan Africa (SSA), BCG and OPV are sched-
uled at birth in 48 and 39 of them, respectively, whilst only eight
countries have introduced HBV vaccine at the birth [6]. According
to 2014 WHO/UNICEF reports, coverage of third dose of HBV vac-
cine, BCG and third dose of OPV in infants in the WHO  Africa region
was 77%, 84% and 77%, respectively [7]. Nevertheless, these ﬁgures
were estimated at deﬁned time points (i.e. 12–23 months of age)
without considering the national policy and timing of vaccines [8].
For example, recent studies in SSA reported BCG vaccine coverage
mostly by 4 or 8 weeks of age [9–13], and few assessed coverage at
birth or at 7 days of age [14,15].
In The Gambia, a west-African country with high rates of
neonatal and infant mortality [16] and high chronic HBV preva-
lence (>8%) according to the WHO  classiﬁcation [17–19], the EPI
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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chedule includes HBV vaccine, BCG and OPV immunization at birth
r as soon as possible after birth. Although the coverage of these
accines is above 95% [20], two previous small studies described
mportant delays in BCG administration [9,10].
Here, we present a large study assessing coverage and timing
f the birth dose vaccines (HBV vaccine, BCG and OPV) over a 10-
ear period (2004–2014) in The Gambia using the Farafenni Health
nd Demographic Surveillance System (FHDSS). We  also assessed
emographic and epidemiological factors associated with delayed
accination.
. Method
.1. Study sites and data collection
The Farafenni Health and Demographic Surveillance System
FHDSS) in the North Bank Region of The Gambia was  established in
981 [21]. The details of FHDSS have been described in elsewhere
21]. Brieﬂy, the FHDSS covered all residents living in Farafenni
own and surrounding villages located in North Bank Region of
he Gambia. In 2012, the FHDSS covered a population of 50,455.
rained ﬁeld workers visit each household every four months to
ollect demographic data (e.g. births, deaths, in and out migrations).
accination status of children under 5 years of age is collected from
heir infant welfare cards. If this is not available, children are con-
idered unvaccinated. They constitute no more than 2% of children
nder 5 years of age [22].
For the purposes of this study, we divided the area covered by
he FHDSS into four regions reﬂecting the catchment areas of the
espective health facilities that serve the FHDSS population. These
re rural west (11 villages), the catchment area of Illiasa Minor
ealth Centre; rural east (31 villages) served by Ngaiyen Sanjal andarafenni.
Sarakunda Minor Health Centres in the north and south respec-
tively; and peri-urban (23 villages located between 5 and 10 km
from the central point of the urban area) and urban areas (49 blocks)
(Fig. 1). The peri-urban and urban regions access health care from
a major health centre and a regional hospital located in Farafenni
town. The urban area is divided into residential blocks with roughly
similar number of inhabitants.
The vaccine data were collected prospectively since mid-2003
as part of routine FHDSS data collection. Socio-economic data were
collected in two surveys conducted in 2007 and 2013. Place of birth
is collected prospectively since January 2014, as well as other birth
information such as birth weight and assistance at delivery.
2.2. Vaccine delivery
Health facilities within the study area are supplied with vac-
cines by the central medical stores in Banjul, Gambian capital, every
month through the ofﬁce of the Regional Health Team in Farafenni,
and stored in fridges with temperature operated by solar panels.
Each facility conducts reproductive and child health (RCH) clin-
ics once or twice a week; and undertakes visits to a set schedule
of outreach clinics depending on the population of the vicinity
within its catchment areas on other days of the week [23]. Vac-
cines are administered and only available through RCH clinics and
these outreach clinics (Fig. 1). Even the hospital in the study area,
Farafenni Hospital, does not vaccinate children born in the hospital.
Both health facilities and outreach clinics use multiple-dose vials
for monovalent HBV vaccine (10 doses/vial), BCG (20 doses/vial)
and OPV (20 doses/vial). As recommended by the WHO,  an opened
vial needs to be used within six hours for BCG and within 28 days
for HBV vaccine and OPV [24].
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Fig. 2. BCG, OPV and HBV cumulative vaccine covera
.3. Statistical analysis
We  deﬁned the “Birth dose” of vaccine as vaccination at the day
f birth or the day after (day 0 or day 1). Vaccination coverage for
he ﬁrst dose of HBV vaccine, BCG and OPV at the different time
oints [at birth (day 0–1), day 7, day 28, 6 months and 1 year] were
alculated for each year by dividing the number of vaccinated chil-
ren by the number of live births. The trend of vaccine coverage
ver the study year was tested by trend test.
Using the data from January 2011 and December 2014, fac-
ors associated with the timely administration of the ﬁrst dose of
accine [deﬁned as vaccination at birth (day 0–1) and day 7 after
irth] were identiﬁed by computing odds ratio using logistic regres-
ion. p-Value was tested using likelihood ratio tests. Children born
etween 2004 and 2010 were excluded from this analysis because
ocio-economic status (SES) was missing. The exposures of inter-
st were area of residence (west-rural, east-rural, peri-urban and
rban) and distance to vaccination delivery point (i.e. health centre
r outreach clinic). We  also assessed the association between the
imely administration and other variables [year of birth, sex, eth-
icity, season of birth, maternal age, birth spacing, presence of elder
ibling(s), maternal education levels and SES]. The factors found to
e associated in the univariable analysis (p < 0.2) were included in a
ultivariable logistic regression model. The impact of the place of
irth and category of delivery assistant on vaccine coverage at birth
as examined using the 2014 data as information on place of birth
nly collected from January 2014. All the analyses were performed
sing STATA 12.0.
SES index were created using asset ownership and household
aterial by principal component analysis and divided into ﬁve
ategories [25]. The locations of villages were mapped using Geo-
raphic Information System (GIS). We  created the FHDSS map  using
GIS and data of OpenSourceMap. The direct distances from vil-
ages to vaccination sites were measured using QGIS software.
. ResultsBetween 2004 and 2014, 10,851 children were born in the FHDSS
nd only 14 of these children (0.13%) did not have the infant welfare
ard. The median age on receipt of the ﬁrst dose of each of three
tudy vaccines was 24 days [Interquartile range (IQR): 16–35 daysring infancy, from 2005 to 2014, in Farafenni HDSS.
for HBV vaccine and BCG, and 16–34 days for OPV]; the overall vac-
cine coverage by the age of 12 months was 93.6% for HBV vaccine,
95.3% for BCG and 95.9% for OPV (Fig. 2). Because the vast majority
[91.8% (9963/10,851)] of infants received these three vaccines on
the same day, we  only present the data for HBV vaccine in further
analysis on risk factors for delayed birth vaccination assuming that
those factors are the same factors associated with delayed BCG and
OPV vaccination.
First dose of HBV vaccine coverage at birth (day 0–1), day 7, day
28, 6 months and 12 months over the study period (2004–2014)
was 1.1% (117/10,851), 5.4% (586/10,851), 58.4% (6340/10,851),
93.1% (10,100/10,851) and 93.6% (10,162/10,851) respectively. First
dose of vaccine coverage did not increase from 6 months to 12
months (Fig. 2). Vaccine coverage at day 1 and 7 were simi-
lar throughout the study period (p-value for trend p = 0.516 and
p = 0.662 at day 1 and 7, respectively). In contrast, there was an
increase in coverage at day 28 and 6 months between 2004 and
2014 [from 46.7% to 62.2% (p-value for trend test <0.001 at day 28;
and from 87.6% to 96.2% at 6 months (p-value for trend <0.001))
(Fig. 2).
3.1. Factors associated with vaccination within 7 days of birth
A total of 5994 infants born in the FHDSS between January 2011
and December 2014 were included in the risk factors analysis. Over-
all, 44.2% of these children lived in rural areas and approximately
50% lived within 1 km from a vaccination delivery point. Ethnic-
ity, maternal age, presence of sibling(s), maternal education and
SES index varied according to the study regions (Table 1). Approx-
imately 60% of these children were born in a health facility.
The multivariable analysis shows that children in rural areas
were more likely to be vaccinated by day 7 than those in urban
and peri-urban areas [east-rural compared to urban area: Adjusted
Odds Ratio (AOR) 6.13, 95%CI: 3.20–11.74; west-rural compared to
urban area: AOR 6.72, 95%CI: 3.66–12.34] (Table 2). Increasing dis-
tance from a vaccination delivery point decreased the chance of
vaccination by day 7 (<1 km vs 1–2 km AOR 0.50, 95%CI: 0.35–0.70,
vs 2 km AOR 0.41, 95%CI: 0.24–0.70). Ethnicity and education
were also associated with vaccine coverage by day 7. Vaccine cov-
erage among Fulas was signiﬁcantly lower than among Wollof, the
most common ethnic group (AOR 0.60, 95%CI: 0.39–0.91). Children
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Table 1
Baseline characteristics of the study participants by region within the area of the Farafenni Health and Demographic Surveillance System from 2011 to 2014 (N = 5994).
Variable Category Total West-rural East-rural Peri-urban Urban
N  = 5994 N = 767 N = 1882 N = 795 N = 2550
Sex Male 3114 (52.0) 401 (52.3) 1015 (53.9) 394 (49.6) 1304 (51.2)
Female 2880 (48.0) 366 (47.7) 867 (46.1) 401 (50.4) 1246 (48.8)
Ethnicity Wollof 2807 (46.8) 57 (7.4) 1089 (57.9) 531 (66.8) 1130 (44.3)
Mandinka 1710 (28.5) 561 (73.1) 300 (15.9) 66 (8.3) 783 (30.7)
Fula 1241 (20.7) 117 (15.3) 483 (25.7) 187 (23.5) 454 (17.8)
Others 236 (3.9) 32 (4.2) 10 (0.5) 11 (1.4) 183 (7.2)
Season of birth Wet  (June–October) 2933 (48.9) 393 (51.2) 932 (49.5) 367 (46.2) 1241 (48.6)
Dry  (November–May) 3061 (51.1) 374 (48.8) 950 (50.5) 428 (53.8) 1309 (51.4)
Maternal age (years) 19 728 (12.1) 80 (10.4) 246 (13.1) 81 (10.2) 321 (12.6)
20–29 3035 (50.6) 341 (44.5) 903 (48.0) 407 (51.2) 1384 (54.3)
30– 2232 (37.2) 346 (45.1) 733 (38.9) 307 (38.6) 845 (33.2)
Year  of birth 2011 1334 (22.3) 176 (22.9) 424 (22.5) 164 (20.6) 570 (22.4)
2012 1649 (27.5) 225 (29.3) 519 (27.6) 221 (27.8) 684 (26.8)
2013 1519 (25.3) 183 (23.9) 475 (25.2) 188 (23.6) 673 (26.4)
2014 1491 (24.9) 183 (23.9) 464 (24.7) 222 (27.9) 622 (24.4)
Birth  spacing Less than 2 years 644 (10.7) 85 (11.1) 215 (11.4) 82 (10.3) 263 (10.3)
Over 2 years 5348 (89.2) 682 (88.9) 1666 (88.5) 713 (89.7) 2287 (89.7)
Siblings
(N  = 5943)
No 1629 (27.4) 164 (21.6) 346 (18.4) 188 (23.7) 931 (36.9)
Yes  4315 (72.6) 597 (78.4) 1521 (81.1) 604 (76.3) 1593 (63.1)
Distance to vaccine
delivery point
<1 km 2940 (49.1) 380 (49.5) 1232 (65.5) 256 (32.2) 1072 (42.1)
1–2  km 2462 (41.1) 228 (29.7) 490 (26.0) 268 (33.7) 1476 (57.9)
>2  km 592 (9.9) 159 (20.7) 160 (8.5) 271 (34.1) 2 (0.1)
Maternal education
(N = 5013)
No 790 (15.8) 53 (8.1) 86 (5.3) 122 (19.1) 529 (25.3)
Koranic 3362 (67.1) 536 (82.2) 1390 (85.3) 443 (69.2) 993 (47.5)
Basic 527 (10.5) 49 (7.5) 125 (7.7) 44 (6.9) 309 (14.8)
Senior 334 (6.7) 14 (2.2) 29 (1.8) 31 (4.8) 260 (12.4)
SES  index
(N = 5463)
1st poor 1080 (19.8) 183 (26.0) 631 (35.9) 230 (31.5) 36 (1.6)
2nd 966 (17.7) 284 (40.4) 465 (26.5) 174 (23.8) 43 (1.9)
3rd 1058 (19.4) 131 (18.6) 482 (27.4) 215 (29.5) 230 (10.1)
4th  1118 (20.5) 84 (11.9) 171 (9.7) 99 (13.6) 764 (33.6)
5th  wealthy 1241 (22.7) 21 (3.0) 7 (0.4) 12 (1.6) 1201 (52.8)
Place  of birth (2014)
(N = 1490)
Own/relative’s home 600 (40.3) 97 (53.0) 251 (54.1) 100 (45.1) 152 (24.5)
Health centers 268 (18.0) 68 (37.2) 191 (41.2) 3 (1.4) 6 (1.0)
Hospital 622 (41.7) 18 (9.8) 22 (4.7) 119 (53.6) 463 (74.6)
Delivery assistant
(2014)
(N = 1490)
Midwife 444 (32.4) 58 (31.7) 140 (30.2) 61 (27.5) 223 (35.9)
TBA 444 (29.8) 89 (48.6) 204 (44.0) 80 (36.0) 71 (11.4)
Doctor 74 (5.0) 7 (3.8) 10 (2.2) 10 (4.5) 47 (7.6)
b
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cOther 470 (31.5) 
None 20 (1.3) 
orn to mothers with high education level had signiﬁcantly higher
accine coverage at 7 days than children born from uneducated
others (AOR 2.43, 95%CI: 1.17–5.07) (Table 2).
Vaccination by day 1 was signiﬁcantly higher in rural than urban
reas (AOR 4.61, 95%CI: 2.27–9.36) (Supplementary Table 1). In
014, more than half (59.7%) of the 1490 children were born in
 health facility (hospital or health center); among these, only 0.6%
ere vaccinated by day 1 and 3.8% by day 7 after birth (Table 3),
ot higher percentage than children born in other locations.
Supplementary Table 1 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2016.05.
17.
. Discussion
Despite the high vaccination coverage by 6 months of age, the
roportion of Gambian infants having received the three recom-
ended vaccines within one week of age was particularly low.ew factors were found to be associated with delayed vaccination,
amely living in urban and peri-urban settings, long distance from
accination delivery points, Fula ethnicity, and low maternal edu-
ation. Interestingly, being born in any health facility did not have28 (15.3) 104 (22.4) 68 (30.6) 270 (43.5)
1 (0.6) 6 (1.3) 3 (1.4) 10 (1.6)
any effect on early vaccination, indicating the need to improving
awareness on the timely administration of vaccines among health
workers. In addition, there is the need for integrating these vac-
cines in the maternal and neonatal services as is already the case
with the tetanus toxoid vaccine. The use of multi-dose vials and
the limited time for their use is probably a barrier for this proposed
option, specially for BCG where the 20 doses of the multi-vial need
to be ﬁnalized within hours.
Previous studies, both in The Gambia and in other SSA countries,
assessed vaccine coverage at different time points after birth,
mostly at 12–23 months [22,26,27], and sometimes at 4 and 8
weeks after birth [9–13,28–30]. The few studies that assessed BCG
and the ﬁrst OPV dose at day 7 reported low coverage, in Ghana 38%
for BCG and 41% for OPV [14] and in Guinea-Bissau 11% for BCG [15].
In The Gambia, the seemingly better coverage, timely administra-
tion of BCG in 90.7% [9] and 94.2% [10] of children, is probably due
to the deﬁnition of timely vaccination, which was considered so
within the ﬁrst 8 weeks of life.The current WHO  recommendation to provide HBV vac-
cine within 24 h of delivery aims at preventing hepatitis B
mother-to-child transmission [4]. This is extremely important as
perinatal maternal transmission not only increases the risk of
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Table  2
Factors associated with vaccination at day 7 after birth in the Farafenni Health and Demographic Surveillance System, 2011–2014 (N = 5994).
Variables Total Day 7 after birth
No. (%) Crude ORa(95%CIc) pd Adjusted ORb(95%CIc) pd
Area
Urban 2550 43 (1.7) 1 (reference) <0.001 1 (reference) <0.001
Peri-urban 795 14 (1.8) 1.04 (0.57–1.92) 1.59 (0.69–3.64)
West-rural 767 66 (8.6) 5.49 (3.70–8.13) 6.13 (3.20–11.75)
East-rural 1882 190 (10.1) 6.54 (4.67–9.16) 6.72 (3.66–12.33)
Distance to vaccine delivery point
<1 km 2940 218 (7.4) 1 (reference) <0.001 1 (reference) <0.001
1–2  km 2462 72 (2.9) 0.38 (0.29–0.49) 0.50 (0.35–0.70)
>2  km 592 23 (3.9) 0.50 (0.33–0.78) 0.41 (0.24–0.70)
Sex
Boys  3114 162 (5.2) 1 (reference) 0.94
Girls 2880 151 (5.2) 1.01 (0.80–1.27)
Ethnicity
Wollof 2807 140 (5.0) 1 (reference) <0.001 1 (reference) 0.014
Mandinka 1710 117 (6.8) 1.40 (1.09–1.80) 1.18 (0.83–1.70)
Fula  1241 52 (4.2) 0.83 (0.60–1.15) 0.60 (0.40–0.91)
Others 236 4 (1.7) 0.33 (0.12–0.9) 0.67 (0.23–1.96)
Year  of birth
2011 1334 69 (5.2) 1 (reference) 0.08 1 (reference) 0.06
2012  1649 83 (5.0) 0.97 (0.70–1.35) 1.19 (0.81–1.73)
2013  1520 97 (6.4) 1.25 (0.91–1.72) 1.36 (0.93–1.99)
2014  1491 64 (4.3) 0.82 (0.58–1.17) 0.81 (0.53–1.23)
Season of birth
Wet  2933 160 (5.5) 1 (reference) 0.45
Dry  3061 153 (5.0) 0.91 (0.73–1.14)
Mother age
19 728 32 (4.4) 1 (reference) 0.22
20–29 3034 151 (5.0) 1.14 (0.77–1.68)
30 2231 130 (5.8) 1.35 (0.91–2.00)
Birth spacing
Less than 2 years 645 45 (7.0) 1 (reference) 0.041 1 (reference) 0.056
Over  2 years 5348 268 (5.0) 0.7 (0.51–0.97) 0.67 (0.45–1.00)
Sibling
No  1629 75 (4.6) 1 (reference) 0.165 1 (reference) 0.75
Yes  4315 237 (5.5) 1.2 (0.92–1.57) 0.93 (0.64–1.35)
Maternal education level
No 790 23 (2.9) 1 (reference) 0.005 1 (reference) 0.027
Koranic 3362 198 (5.9) 2.09 (1.35–3.24) 0.97 (0.57–1.64)
Basic  527 28 (5.3) 1.87 (1.07–3.29) 1.46 (0.77–2.77)
Senior 334 16 (4.8) 1.68 (0.87–3.22) 2.43 (1.17–5.06)
SES  index
1st Poor 1080 71 (6.6) 1 (reference) <0.001 1 (reference) 0.50
2nd  966 88 (9.1) 1.42 (1.03–1.97) 1.24 (0.85–1.80)
3rd  1058 61 (5.8) 0.87 (0.61–1.24) 0.95 (0.64–1.43)
4th  1118 39 (3.5) 0.51 (0.34–0.77) 1.19 (0.73–1.93)
5th  Wealthy 1241 20 (1.6) 0.23 (0.14–0.38) 0.83 (0.39–1.75)
a Odd Ratio.
irth, b
c
(
b
t
A
n
ﬁ
c
w
V
v
a
Vb Odds Ratio adjusted for area, distance from vaccine location, ethnicity, year of b
c 95% conﬁdence interval.
d p-Value tested by likelihood ratio test.
hronic HBV infection [31], but also that of severe liver disease
i.e. liver cancer) amongst chronic carriers [32,33]. In The Gam-
ia, approximately 2 out of 3 chronic carriers who  require antiviral
herapy are attributable to the mother-to-child transmission [33].
lthough all SSA countries have introduced HBV vaccine into their
ational immunization programmes, most countries provide its
rst dose at 6–8 weeks of age. This happens due to the logisti-
al challenges to provide the vaccine within 24 h of birth in areas
here home delivery is common. In addition, the Global Alliance for
accines and Immunizations (GAVI) provides only the pentavalent
accine (DTP-HepB-Hib) which is not licensed to be administered
t birth. Consequently, only eight SSA countries (Botswana, Cape
erde, Djibouti, The Gambia, Namibia, Nigeria, Mauritania, and Saoirth spacing, sibling, maternal education and SES index.
Tome and Principe) have a policy to administer HBV vaccination at
birth. Coverage and timeliness have been determined only as part
of a vaccine trial [34,35]; or in Nigeria from a health facility-based
cross-sectional study [36,37]. Ours is the ﬁrst population-based
study in SSA estimating HBV vaccine birth dose coverage in real-life
conditions.
In 2014, the WHO’s Strategic Advisory Group of Experts on
immunization (SAGE) recognized a possible beneﬁcial non-speciﬁc
effect of BCG on all-cause mortality in addition to the potential
direct effect on TB [38,39]. In addition, a recent randomized con-
trolled trial showed a reduction in all-cause mortality when OPV
was given within two days of birth [40]. Because more than half of
infant mortality occurs during the ﬁrst week of life, if non-speciﬁc
3340 R. Miyahara et al. / Vaccine 34 (2016) 3335–3341
Table 3
Vaccine coverage at birth (day 1) and day 7 after birth by location of birth and by the nature of assistance at delivery in 2014 (N = 1490).
Number (%) Day 0–1 (at birth)
No. (%)
AORa (95%CIc) pd Day 7 after birth
No. (%)
AORb (95%CIc) pd
N = 1490 13 (0.87)
Place of birth
Home 600 (40.3) 8 (1.3) 1 (reference) 0.29 32 (5.2) 1 (reference) 0.34
Health center 268 (18.0) 2 (0.8) 0.32
(0.06–1.59)
24 (8.5) 1.49 (0.72–3.07)
Hospital 622 (41.7) 3 (0.5) 1.19
(0.21–6.76)
10 (1.6) 0.63 (0.20–2.03)
Delivery assistant
Midwife 482 (32.3) 4 (1.6) 1 (reference) 0.45 29 (6.4) 1 (reference) 0.90
TBA  444 (29.8) 7 (0.8) 1.58
(0.43–5.68)
23 (4.6) 0.93 (0.44–2.01)
Doctor 74 (5.0) 0 (0) – 2 (2.7) 0.50 (0.06–4.22)
Other 470 (31.5) 2 (0.4) 0.59
(0.11–3.27)
12 (2.5) 0.83 (0.34–2.00)
None 20 (1.3) 0 (0) – 0 (0) –
a Odds ratio adjusted for living areas, distance to vaccine delivery point and ethnicity.
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Acknowledgmentsb Odds ratio adjusted for area, distance from vaccine delivery point, ethnicity, bir
c 95% conﬁdence interval.
d p-Value tested by likelihood ratio test.
ffect of BCG and OPV in fact occur these vaccines should be given
mmediately after birth. Further research is needed to better under-
tand the beneﬁts of such a strategy.
Several factors were associated with low vaccine coverage by
he ﬁrst week of life. Distance to a vaccination delivery point
as one of these and is consistent with previous studies in Africa
27,41]. Contrary to previous reports of better coverage in urban
reas [14,42,43], in Farafenni, rural areas had high vaccine coverage
y day 7 after birth. The difference between rural and urban areas
ould be linked to the primary health care (PHC) system, introduced
n rural Gambia in 1978, which consists in village-based traditional
irth attendants and village health workers operating under the
upervision of community health nurses [21]. As part of this system,
illage health workers have an active role in informing people of the
ate of outreach clinics, possibly helping in the earlier vaccination
ptakes observed in rural areas.
Greater delay in vaccine birth doses among Fulas was consistent
ith a previous report [9]. Also in agreement with a previous report,
e found an association between maternal education and delayed
nfant’s immunization [13].
A recent WHO  systematic review on factors associated with
igher uptake of the HBV vaccine birth dose identiﬁed: integra-
ion of the birth dose vaccine with maternal/newborn services,
ome visits by village health workers, vaccine storage outside the
old-chain and use of a single-dose injection pre-ﬁlled with HBV
accine [44]. The evidence was based mainly on studies done in Asia
hile no such information has been collected in SSA [44]. Further
esearch is therefore needed in SSA to establish the most suitable
ntervention in the continent.
The strength of this study is the use of population-based data
ollected over a period of more than 10 years. Vaccination dates
ere collected prospectively from infant welfare cards, which were
ostly available, minimizing selection bias, and did not rely on
other’s recall. A limitation of this study is vaccine coverage may
ave been overestimated, as children dying during the early neona-
al period, less likely to have been vaccinated, may  not have been
egistered in the FHDSS. However, neonatal mortality is a relatively
are event, epidemiologically speaking. The direct distance from
he residence to the vaccination delivery point is only a surrogate
arker for distance. Although vaccine coverage may  differ in dif-erent areas within the country, previous data from a smaller study
n Sibanor show a similar low coverage of birth vaccines during
he early neonatal period. In addition, because timely vaccination
overage was low (approximately 1% at days 0–1 and 5% at daycing, sibling, maternal education and SES index.
7), statistical power was  insufﬁcient to evaluate factors associated
with vaccination at this time point.
5. Conclusion
In conclusion, vaccine coverage at birth and the subsequent
neonatal period was extremely low in The Gambia over the last
10 years. Integration of the birth dose vaccines within the mater-
nal and neonatal services in all health facilities could increase early
vaccination coverage, at least among children born in health facili-
ties that represent the majority of the population. There is the need
to investigate this and other potential approaches to improve birth
dose vaccine coverage in SSA.
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